Advancing innovative cancer therapies depends on one critical factor: ensuring patients can access early-phase clinical trials. For many individuals with advanced cancers, particularly those driven by complex mutations such as KRAS, treatment options remain limited, and participation in Phase I research can offer a path to emerging therapies. Expanding global access to these trials is essential to accelerating innovation and improving patient …
With continued global expansion, NEXT Oncology is one of the world’s largest Phase I Cancer Trial organizations. [SAN ANTONIO, TX – November 5, 2025] NEXT Oncology, an Avacare business, has expanded its services to Asia through a strategic partnership with Kansai Medical University in Osaka, Japan. Under the guidance of Dr. Toshio Shimizu as the Director of the Phase I …
Authors: Marnie Sanders, Vice President, proXimity™, Equicare Health, Inc. Melanie Morris, Associate Director, Precision Site Network, Precision for Medicine Maureen Thompson, Chief Technology Officer, NEXT Oncology This white paper, co-authored by representatives from NEXT Oncology, Precision for Medicine, and Equicare Health, serves as both a case study and a call to action: the future of clinical trials depends on collaboration, technology adoption, …
Phase 1 trial findings published in Nature Medicine show promise for a new approach to targeting colorectal cancer and other tumors expressing CEACAM5. NEXT Oncology’s Dr. Ildefonso Ismael Rodriguez Rivera, a medical oncologist and hematologist in the San Antonio office, has led an innovative Phase 1 clinical trial of precemtabart tocentecan (Precem-TcT) focused on metastatic colorectal cancer, with results now …
With continued global expansion, NEXT Oncology is one of the world’s largest Phase 1 Cancer Trial organizations. (SAN ANTONIO, TX) July 29, 2025 –– NEXT Oncology has expanded its services to Brazil through a strategic partnership with Onco D’Or Oncologia S.A., the subsidiary of Rede D’Or São Luiz (RDOR3) for oncology services, and IDOR – Instituto D’Or de Pesquisa e …
We are so proud that Dr. David Sommerhalder has been selected as a 2025 Health Care Hero in the Medical Research Category by the San Antonio Business Journal. Read more here (subscription required)
ALTA3263 is a potential best-in-class KRAS-selective small molecule inhibitor that potently targets >90% of KRAS mutations. Read More
Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment. Read More
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1/2 clinical study of its potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418, in patients with advanced solid tumors. Read More
Dr. Spira to lead scientific and research strategy, advancing Phase 1 oncology trials. SAN ANTONIO, TX – May 20, 2025 – NEXT Oncology, one of the world’s largest Phase 1 cancer clinical trial centers, has appointed Alex Spira, MD, PhD, FACP, its new Chief Scientific Officer. Dr. Spira, who currently leads NEXT Oncology – Virginia, will now oversee the company’s …
